Dabogratinib (ACH)

About Tyra Biosciences

Tyra Biosciences is focused on advancing a robust pipeline of selective FGFR inhibitors for oncology and genetically defined conditions. Its core technology platform enables rapid structure-based design to create molecules that address key limitations of current therapies, such as resistance mutations and off-target toxicity. With multiple clinical-stage assets, including dabogratinib in Phase 2 and TYRA-200/430 in Phase 1, the company is targeting significant markets in achondroplasia, bladder cancer, and cholangiocarcinoma.

Therapeutic Areas